RxDoctor Payments Data

Carey-Walter Closson, MD

Interventional Pain Medicine · Charlotte, NCNPI 1336230416

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Medtronic at 39.1% of the total. Reporting peaked in 2022 at $6,733 and has fallen 81.1% since, to $1,270 in 2025.

$13,726in general payments, 2019–2025

Across 317 payments — averaging $43.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$2K
  • Abbott$1K
  • Spinal Simplicity, LLC$894
  • Amgen$853
  • Nevro Corp.$599
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$5,00036%
  • Travel & lodging$1,89714%
  • Food & beverage$6,83050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,726 in reported general payments places this provider in the 75th percentile of 45 interventional pain medicine providers in North Carolina.

See all interventional pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$208,326
Medicare patients
420
Services billed
1,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl26$21,341
Xtampza ErOxycodone Myristate13$7,571
OxycontinOxycodone Hcl16$7,557
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen169$4,869
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen125$2,560
Morphine Sulfate ErMorphine Sulfate43$2,104
Gabapentin108$1,902
Oxycodone Hcl122$1,898
Fentanyl13$1,819
Pregabalin94$1,634
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol13$1,487
Tramadol Hcl93$754
Duloxetine Hcl20$567
Baclofen21$432
Methocarbamol39$329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$184$28,91239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 45 interventional pain medicine providers in North Carolina.

Other interventional pain medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →